Hyloris Pharmaceuticals' Partner Strikes Exclusive Licensing Deal for Painkiller Maxigesic in China

MT Newswires · 2d ago
12:34 AM EDT, 07/15/2026 (MT Newswires) -- Hyloris Pharmaceuticals' (HYL.BR) partner, AFT Pharmaceuticals, signed an exclusive licensing deal with Chengdu Tongde Pharmaceuticals to market and develop painkiller Maxigesic IV in mainland China, according to a Tuesday release. Tongde will finance and conduct chemistry, manufacturing, and control activities and clinical studies to win regulatory approval for the intravenous drug in China. After Maxigesic is approved and commercialized, the Chinese pharmaceutical company will also pay royalties on net sales, with the Belgium-listed specialty biopharma company receiving a minority share of the payments. With the signing of the exclusive agreement, AFT terminated its previous licensing contract for Maxigesic in China.